The different impact of brca mutations on the survival of epithelial ovarian cancer patients: A retrospective single-center experience

D. Lorusso, F. Cirillo, M. Mancini, G. B. Spatti, B. Grijuela, A. Ditto, F. Raspagliesi

Research output: Contribution to journalArticle

Abstract

Objectives: The objective of this study was to examine whether the oncologic outcomes of BRCA1-associated and BRCA2-associated ovarian cancers correlate differently. Methods: Genetic data and clinical characteristics were correlated with progression-free survival (PFS) and overall survival (OS). Results: Data from 147 BRCA-mutated patients (119 BRCA1-positive and 28 BRCA2-positive) were analyzed. At a median follow-up of 69 months, the median PFS was 27.2 and 45.46 months for BRCA1 and BRCA2 patients, respectively (p = 0.03). Median OS was 77.23 and 111.47 months for BRCA1 and BRCA2 patients, respectively (p = 0.08). Conclusion:BRCA2 mutations confer PFS and a trend to OS advantage compared with the BRCA1 mutation in BRCA-mutated epithelial ovarian cancer patients.

Original languageEnglish
Pages (from-to)122-127
Number of pages6
JournalOncology
Volume85
Issue number2
DOIs
Publication statusPublished - Aug 2013

Keywords

  • BRCA mutation carriers
  • Ovarian cancer
  • Platinum chemotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'The different impact of brca mutations on the survival of epithelial ovarian cancer patients: A retrospective single-center experience'. Together they form a unique fingerprint.

  • Cite this